Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.63 |
| ▸ | FLT1 | P17948 | 3/20 | 0.63 |
| ▸ | FLT4 | P35916 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | KIT | P10721 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.47 |
| ▸ | TEK | Q02763 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740759 | 0.93 | KDR (0.59) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL272837 | 0.86 | KDR (0.56) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2748909 | 0.86 | KDR (0.67) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL4548727 | 0.86 | KDR (0.78) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2747970 | 0.85 | KDR (0.55) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL5740763 | 0.83 | KDR (0.58) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL3582067 | 0.83 | KDR (0.53) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL10260360 | 0.83 | KDR (0.61) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL273408 | 0.83 | KDR (0.63) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2708711 | 0.83 | KDR (0.64) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2574340-A2 | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor | Novartis AG (CH) | 2013-04-03 | — | — | EP | claimed |
| EP-2007391-B1 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR | NOVARTIS AG (CH) | 2012-12-19 | — | — | EP | claimed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | claimed |
| US-20090286803-A1 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | claimed |
| EP-2007391-A2 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR | Novartis AG (CH) | 2008-12-31 | — | — | EP | claimed |
| WO-2007116029-A2 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | claimed |
| EP-2574340-A2 | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor | Novartis AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| EP-2007391-B1 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR | NOVARTIS AG (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | KDR 354/4885FLT1 89/4885FLT4 125/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | KDR 826/4885FLT1 638/4885FLT4 944/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885FLT4 2/4885 |
| US-20090286803-A1 | COMBINATION COMPRISING A) A PYRIMIDYLAMINOBENZAMIDE COMPOUND, AND B) A THR315LLE KINASE INHIBITOR | MAP3K5, CHEK2, CDK2 | KDR 651/4885FLT1 615/4885FLT4 505/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | KDR 1319/4885FLT1 1353/4885FLT4 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.